Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors ; volume:41 ; number:1 ; day:9 ; month:11 ; year:2023 ; pages:92-112 ; date:1.2024
Advances in therapy ; 41, Heft 1 (9.11.2023), 92-112, 1.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02652-5
- URN
-
urn:nbn:de:101:1-2024033111115512255166
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Verma, Subodh
- Mudaliar, Sunder
- Greasley, Peter J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?